Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Hematologic Diseases 2Preleukemia 1Myeloproliferative Disorders 1Leukemia, Myeloid, Accelerated Phase 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 15fludarabine phosphate 12Filgrastim 10Peripheral Blood Stem Cell Transplantation 9ruxolitinib 8Decitabine 8fludarabine 7Tacrolimus 7Etoposide 7Melphalan 6Cytarabine 6Azacitidine 6Vorinostat 5Mycophenolic Acid 5Ipilimumab 5venetoclax 4Specimen Handling 4Sirolimus 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4ivosidenib 3fedratinib 3aldesleukin 3Whole-Body Irradiation 3Rituximab 3Radiotherapy 3Nivolumab 3Methylprednisolone 3Imatinib Mesylate 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myeloproliferative Disorders × lintuzumab × Clear all
NCT00283114 2014-12-18

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Seagen Inc.

Phase 1 Completed
82 enrolled
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡